medigraphic.com

2007, Number 3

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2007; 45 (3)

Nesiritide, a Novel Treatment for Heart Failure

Francisco-Méndez G

Language: Spanish
References: 26
Page: 281-290
PDF size: 151.96 Kb.


ABSTRACT

Nesiritide, is a recombinant form of human-B-type natriuretic peptide (hBNP) used for the therapy of acute decompensated heart failure. hBNP produces natriuresis, diuresis, hypotension, and smooth muscle relaxation preventing myocardial fibrosis and vascular smooth muscle cell proliferation. Nesiritide treatment of patients with heart failure causes balanced arterial and venous dilatation with reduction in the pulmonary capillary wedge pressure (PCWP) and increases the cardiac index. It is administered intravenously with a recommended dosage as intravenous bolus of 2 mg/kg/min followed by a continuous infusion of 0.01 mg/kg/min for less than 48 hours. Clinical experience has shown that in patients with heart failure, this drug reduces PCWP, increases cardiac index without changes in heart rate, with the subsequent improvement in clinical symptoms of dyspnea after 3 hours of treatment. Also, there is evidence of less ventricular tachyarrhytmia when compared with dobutamine and better tolerance with less secondary effects when compared with nitroglycerin. It has been suggested that there is an increase in the mortality hazard ratio at 30 days with this treatment, however clinical trials using Nesiritide did not analyze mortality at short or long term as primary end-point. Recently published meta-analysis reported that there is no-increase in mortality at 30 days or 6 months with this treatment. Nesiritide is a novel and effective option for the medical treatment of acute decompensated heart failure.


REFERENCES

  1. McMurray JJV, McDonagh TA, Morrison CE, Dargie HJ. Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J 1993;14:1158-1162.

  2. Cowie MR, Mosterd A, Wood DA. The epidemiology of heart failure. Eur Heart J 1997;18:208-225.

  3. Stewart S, MacIntyre K, MacLeod MMC, Bailey AEM, Capewell S, McMurray JJV. Trends in hospitalization for heart failure in Scotland 1990-1996. An epidemic that has reached its peak? Eur Heart J 2001;22:209-217.

  4. Cowie MR. Annotated references in epidemiology. Eur J Heart Failure 1999;1:101-107.

  5. McMurray JJV, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000;83:596-602.

  6. O’Connell JB. The economic burden of heart failure. Clin Cardiol 2000;23(Suppl III):6-10.

  7. Hunt SA, Baker DW, Chin MH. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001;104: 2996-3007.

  8. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-1560.

  9. Nieminen MS, Böhm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.

  10. Elkayam U, Tasissa G, Binanay C, Wagner L, Gheorghiade M, Warnica J et al. Use and impact of inotropes and vasodilators therapy during heart failure hospitalization in the ESCAPE trial. Circulation 2004;110(17 Suppl 3): Abstract 2415.

  11. Keating GM, Goa KL. Nesiritide. A review of its use acute decompensated heart failure. Drugs 2003;63:47-70.

  12. US Food and Drug Administration. FDA approves acute congestive heart failure treatment. 301-827-6242. 13-8-2001.

  13. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure. A randomized controlled trial. JAMA 2002;287:1531-1540.

  14. Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis 2002;44: 293-321.

  15. Hobbs RE, Miller LW, Bott-Silverman C, James KB, Rincon G, Grossbard EB. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;78:896-901.

  16. Marcus LS, Hart D, Packer M. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94:3184-3189.

  17. Abraham WT, Lowes BD, Ferguson DA. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human natriuretic peptide in patients with hemodynamically descompensated heart failure. J Card Fail 1998;4:37-44.

  18. Colucci WS. Nesiritide for the treatment of decompensated heart failure. J Card Fail 2001; 7:92-100.

  19. Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999; 34:155-162.

  20. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000;343:246-253.

  21. Scios INC. Intravenous B-type natriuretic peptide. Natrecor (nesiritide). Disponible en http://www.sciosinc.com/pdf/natrecorpi_final.pdf. 2006.

  22. Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study. Am Heart J 2002;144:1102-1108.

  23. Peacock IV WF, Holland R, Gyarmathy R, Dunbar L, Klapholz M, Horton DP. Observation unit treatment of heart failure with nesiritide: Results from the PROACTION trial. J Emerg Med 2005;29:243-252.

  24. Yancy CW, Saltzberg MT, Berkowitz RL, Bertolet B, Vijayaraghavan K, Burnham K et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol 2004;94:595-601.

  25. Topol EJ. Nesiritide – not verified. N Engl J Med 2005;353:113-116.

  26. Scios INC. Effect of Natrecor on mortality (Updated 5-9-05). Data on File. 2005.




2020     |     www.medigraphic.com